Effects of AF102B and tacrine on delayed match-to-sample in monkeys

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 22, Issue 4, 1998, Pages 665-678

  O'Neill, Joseph ^a,b,e   Fitten, L Jaime ^a,b   Siembieda, Douglas ^a   Halgren, Eric ^a,b,c   Kim, Ellen ^a   Fisher, Abraham ^d   Perryman, Kent ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSERM   (France)

^d ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

^e Israel Inst For Biol Research ^*  (United States)

Author keywords

AF102B; Aging; Cholinesterase inhibitors; Monkey; Muscarinic agonists; Tacrine; Working memory

Indexed keywords

CEVIMELINE; TACRINE;

AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; COGNITION; CONTROLLED STUDY; DEMENTIA; DOSE RESPONSE; DRUG EFFECT; INTRAMUSCULAR DRUG ADMINISTRATION; MACACA; NONHUMAN; ORAL DRUG ADMINISTRATION; TASK PERFORMANCE; WORKING MEMORY;

AGE FACTORS; ANIMALS; HUMANS; MACACA RADIATA; MEMORY; MEMORY DISORDERS; PARASYMPATHOMIMETICS; QUINUCLIDINES; REACTION TIME; TACRINE; THIOPHENES;

EID: 0032079064     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(98)00029-3     Document Type: Article

References (46)

1. ADEM, A. (1993). The next generation of cholinesterase inhibitors, Acta Neurol. Scand. Suppl. 149: 106-112.
2. ALHAINEN, K. and RIEKKINEN, P.J. (1993). Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurol. Scand. Suppl. 149: 16-21.
3. ARNSTEN, A.F.T. and CONTANT, T.A. (1992). Alpha-2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task. Psychopharmacology 108: 159-169.
4. BARTUS, R.T. (1979). Physostigmine and recent memory: effects in young and aged nonhuman primates. Science 206: 1087-1089.
5. BARTUS, R.T. and DEAN, R.L. (1988). Tetrahydroaminoacridine, 3.4-diaminopyridine and physostigmine: direct comparison of effects on memory in aged primates. Neurobiol. Aging 93: 51-56.
6. BARTUS, R.T., DEAN, R.L., PONTECORVO, M.J. and FLICKER, C. (1985). The cholinergic hypothesis: A historical overview, current perspective, and future directions. Ann. NY Acad. Sci. 444: 333-358.
7. BUCCAFUSCO, J.J. and JACKSON, W.J. (1991). Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol. Aging 12: 233-238.
8. CORMAN, B., PRATZ, J. and POUJEOL, P. (1985). Changes in anatomy, glomerular filtration and solute excretion in aging rat kidney. Am. J. Physiol. 248: R282-287.
9. DAVIS, R., RABY, C., CALLAHAN, M.J., LIPINSKI, W., SCHWARZ, R., DUDLEY, D.T., LAUFFER, D., REECE, P., JAEN, J. and TECLE, H. (1993). Subtype selective muscarinic agonists: Potential therapeutic agents for Alzheimer's disease. In: Prog. in Brain Res. 98, A.C. Cuello (Ed.), pp. 439-445, Elsevier, New York.
10. DAWSON, G.R. and IVERSEN, S.D. (1993). The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav. Brain Res. 57: 143-153.
11. DUNNETT, S.B. and FIBIGER, H.C. (1993). Role of forebrain cholinergic systems in learning and memory: relevance to the cognitive deficits of aging and Alzheimer's dementia. In: Prog. in Brain Res. 98, A.C. Cuello (Ed.), pp. 413-420, Elsevier, New York.
12. EAGGER, S.A. and HARVEY, R.J. (1995). Clinical heterogeneity: responders to cholinergic therapy. Alz. Dis. and Assoc. Disord., Suppl. 9: 237-42.
13. FISHER, A. and BARAK, D. (1994). Progress and perspectives in new muscarinic agonists. Drug News and Perspectives 7: 453-464.
14. FISHER, A., BRANDEIS, R., KARTON, Y., PITTEL, Z., GURWITZ, D., and HARING, M.S. (1990a). ± -cis-2-methyl-spiro(1,3-oxathiolane-5,3′)quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 257(1): 392-403.
15. FISHER, A., BRANDEIS, R., KARTON, Y., PITTEL, Z., GURWITZ, D., and HARING, M.S. (1990b). AF102B: Rational treatment strategy for Alzheimer's disease: recent advances. Adv. Neurol. 51: 257-259.
16. FISHER, A., BRANDEIS, R., KARTON, Y., PITTEL, Z., GURWITZ, D., HARING, M.S., SAPIR, M., LEVY, A., and HELDMAN, E. (1991). (±)Cis-2-methyl-spiro (1,3-oxathiolane-5,3′)quinnuclidine an M1 selective cholinergic agonist attenuates cognitive dysfunction in an animal model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 257(1): 392-403.
17. FISHER, A. and HELDMAN, E. (1991). (±) Cis-2-methyl-spiro(1,3-oxathiolane-5,3′)quinuclidine (AF102B) a new M1 agonist as a rational treatment strategy in Alzheimer's disease-An overview. In: Basic, Clinical and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, Vol. 35B, T. Nagatsu, A. Fisher and M. Yoshida (Eds.), pp. 309-319, Plenum Press, New York and London.
18. FISHER, A., HELDMAN, E., HARING, R., MESHULAM, H., PITTEL, Z., GURWITZ, D., MARCIANO, D., BRANDEIS, R., SAPIR, M., KARTON, Y., SADOT, E., BARG, Y., PINKAS-KRAMARSKI, R., VOGEL, Z., GINZBURG, I., TREVES, T.A., VERCHOVSKY, R., KLIMOWSKY, S., KORCZYN, A.D. (1995). New M1 agomists: from replacement treatment to delaying the progression of Alzheimer's disease-novel properties. Life Sci. Res. 972: 13-35.
19. FISHER, A., KARTON, Y., HELDMAN, E., GURWITZ, D., HARING, R., MESHULAM, H., BRANDEIS, R., PITTEL, Z., SEGALL, Y., MARCIANO, D., MARKOVITCH, I., SAMOCHA, Z., SHIRIN, E., SAPIR, M., GREEN, B., SHOHAM, G., and BARAK, D. (1993). Progress in medicinal chemistry of novel selective muscarinic agonists. Drug Design and Discovery 9: 221-235.
20. FITTEN, L.J., O'NEILL, J, SIEMBIEDA, D, CRAWFORD, K.C., HALGREN, E, FISHER, A., and PERRYMAN, K.M. (1995). Selective attention-enhancing effects of AF102B and THA in young and mid-aged monkeys. Soc. Neurosci. Abstr. 21(1): 167.
21. FITTEN, L.J., PERRYMAN, K.M., GROSS, P.L., FINE, H., CUMMINS, J. and MARSHALL, C. (1990). Treatment of Alzheimer's Disease with short and long-term oral THA and lecithin: a double blind study. Am. J. Psychiatry 147: 239-242.
22. FLICKER, C., BARTUS, R.T., CROOK, T.H., and FERRIS, S.H. (1984). Effects of aging and dementia upon recent visuospatial memory. Neurobiol. Aging 5: 275-283.
23. GAFFAN, D. and EACOTT, M.J. (1995). Uncinate fascicle section leaves delayed matching-to-sample intact, with both large and small stimulus sets. Exp. Brain Res. 105(1): 175-180.
24. GAMZU, E. (1985). Animal behavioral models in the discovery of compounds to treat memory dysfunction. Ann. NY Acad. Sci. 444: 371-393.
25. HÅKANSSON, L. (1993). Mechanism of action of cholinesterase inhibitors in Alzheimer's disease. Acta Neurol. Scand., Suppl. 149: 7-9.
26. HUDZIK, T.J. and WENGER, G.R. (1993). Effects of drugs of abuse and cholinergic agents on delayed matching-to-sample responding in the squirrel monkey. J. Pharmacol. Exp. Ther. 265(1): 120-127.
27. JACKSON, W.J., BUCCAFUSCO, J.J., TERRY, A.V., TURK, D.J. and RUSH, D.K. (1995). Velnacrine maleate improves delayed matching performance by aged monkeys. Psychopharmacology 119: 391-398.
28. JACKSON, W.J., ELROD, K. and BUCCAFUSCO, J.J. (1989). Delayed matching-to-sample in monkeys as a model for learning and memory deficits: Role of brain nicotinic receptors. Adv. Behav. Biol. 36: 39-52.
29. JORM, A.F. (1986). Effects of cholinergic enhancement therapies on memory function in Alzheimer's disease: a meta-analysis of the literature. Aust. NZ J. Psychiatry 20: 237-240.
30. MESULAM, M.-M., MUFSON, E.J., LEVEY, A.I. and WAINER, B.H. (1983). Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J. Comp. Neurol. 214: 170-197.
31. MOLCHAN, S.E., MARTINEZ, R.A., HILL, J.L., WEINGARTNER, H.J., THOMPSON, K., VITIELLO, B. and SUNDERLAND, T. (1992). Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res. Rev. 17: 215-26.
32. OGURA, H. and AIGNER, T.G. (1993). MK-801 impairs recognition memory in rhesus monkeys: comparison with cholinergic drugs. J. Pharmacol. Exp. Ther. 266(1): 60-64.
33. OSCAR-BERMAN, M. and BONNER, R.T. (1985). Matching-and delayed matching-to-sample performance as measures of visual processing, selective attention, and memory in aging and alcoholic individuals. Neuropsychologia 23: 639-651.
34. PERRYMAN, K.M. and FITTEN, L.J. (1993). Delayed matching-to-sample performance during a double blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease. Life Sci. 53: 479-486.
35. PETERS, A., ROSENE, D.L., MOSS, M.B., KEMPER, T.L., ABRAHAM, C.R., TIGGES, J. and ALBERT, M.S. (1996). Neurobiological bases of age-related cognitive decline in the rhesus monkey. J. Neuropathol. Exp. Neur. 55(8): 861-874.
36. RIDLEY, R.M. and BAKER, H.F. (1991). A critical evaluation of monkey models of amnesia and dementia. Brain Res. Rev. 16: 15-37.
37. RIDLEY, R.M., BAKER, H.F., and MURRAY, T.K, (1988). Basal nucleus lesions in monkeys: recognition memory impairment or visual agnosia? Psychopharmacology 95: 289-290.
38. RUPNIAK, N.M.J., FIELD, M.J., SAMSON, N.A., STEVENSON, M.J. and IVERSEN, S.D. (1990). Direct comparison of cognitive facilitation by physostigmine and tetrahydroaminoacridine in two primate models. Neurobiol. Aging 11: 609-613.
39. SADOT, E., GURWITZ, D., BARG, J., BEHAR, L., GINZBURG, I., FISHER, A. (1996). Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J. Neurochem. 66(2): 877-880.
40. SHERMAN, K.A. and MESSAMORE, E. (1988). Blood cholinesterase inhibitors as a guide to the efficacy of putative therapies for Alzheimer's dementia: comparison of tacrine and physostigmine. In: Current Research in Alzheimer Therapy, E. Giacobini and R.E. Becker (Eds.), pp. 73-86, Taylor and Francis, New York.
41. TAYLOR, P. (1982). Cholinergic agonists. In: Pharmacological Basis of Therapeutics, A.G. Gilman and L.S. Goodman (Eds.), pp. 100-129, MacMillan, New York.
42. TERRY, A.V., JACKSON, W.J. and BUCCAFUSCO, J.J. (1993). Effects of concomitant cholinergic and adrenergic stimulation on learning and memory performance by young and aged monkeys. Cereb. Cortex 3: 304-312.
43. UNO, H. (1997). Age-related pathology and biosenescent markers in captive rhesus macaques. Age 20: 1-13.
44. VOYTKO, M.L. (1997). Functional and neurobiological similarities of aging in monkeys and humans. Age 20: 29-44.
45. VOYTKO, M.L., OLTON, D.S., RICHARDSON, R.T., GORMAN, L.K., TOBIN, J.R. and PRICE, D.L. (1994). Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J. Neurosci. 14(1): 167-186.
46. WENK, G. (1993). A primate model of Alzheimer's disease. Behav. Brain Res. 57: 117-122.